Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Astria Therapeutics, Inc. (ATXS)
|
Add to portfolio |
|
|
|
| Price: |
$6.25
| | Metrics |
| OS: |
28.0
|
M
| |
-24
|
% ROE
|
| Market cap: |
$175
|
M
| |
-76
|
% ROIC
|
|
Net cash:
|
$203
|
M
| |
$7.24
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($55.3)
|
M
| |
|
|
|
EBIT
|
($55.3)
|
M
| |
|
|
| EPS |
($2.63)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.4 | 0.1 |
| Revenue growth | | | | | -100.0% | 33.0% | 276.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.1 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 |
| Gross margin | | | | | | 100.0% | 0.0% | 0.0% |
| Research and development | 34.3 | 15.6 | 25.6 | 18.3 | 17.0 | 18.7 | 25.5 | 23.0 |
| General and administrative | 19.2 | 14.8 | 11.8 | 8.8 | 9.3 | 8.9 | 10.1 | 8.6 |
| EBIT | -53.5 | -31.2 | -37.4 | -27.1 | -26.4 | -27.1 | -35.6 | -31.7 |
| EBIT margin | | | | | | -5418.8% | -9456.9% | -31659.0% |
| Pre-tax income | -51.8 | -194.9 | -37.3 | -26.3 | -25.9 | -27.4 | -36.1 | -32.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -51.8 | -219.3 | -37.3 | -26.3 | -25.9 | -27.4 | -36.1 | -32.6 |
| Net margin | | | | | | -5472.8% | -9590.4% | -32630.0% |
| |
| Diluted EPS | ($3.55) | ($24.58) | ($12.20) | ($2.35) | ($5.12) | ($12.62) | ($2.22) | ($4.06) |
| Shares outstanding (diluted) | 14.6 | 8.9 | 3.1 | 11.2 | 5.1 | 2.2 | 16.2 | 8.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|